Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Labcorp, NowDx collaborate to expand rapid syphilis testing

September 2025—Labcorp and NowDiagnostics are collaborating to expand access to rapid syphilis testing. The companies will distribute First to Know Syphilis Test kits at no cost to select community-based public health organizations across the United States. Labcorp and NowDx distributed kits to more than 15 organizations across the country, including to LGBTQ+ health centers, HIV/AIDS care providers, and safety-net clinics. Labcorp serves as the exclusive commercial laboratory offering the test for health care providers as well as directly to consumers

Qiagen, Incyte to develop CDx for patients with myeloproliferative neoplasms

September 2025—Qiagen is collaborating with Incyte to develop a novel diagnostic panel to support Incyte’s portfolio of investigational therapies, including Incyte’s monoclonal antibody INCA033989, for patients with myeloproliferative neoplasms. Under the terms of the master collaboration agreement, Qiagen will develop a multi­modal panel using next-generation sequencing technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the Illumina NextSeq 550Dx.

SehaMed, New Day Dx to launch ColoHealth in the Middle East

September 2025—SehaMed Global (Bristol, England) announced a strategic distribution agreement with New Day Diagnostics of Knoxville, Tenn., to bring ColoHealth, an FDA-approved blood test for the early detection of colorectal cancer, to patients in Saudi Arabia, the United Arab Emirates, and other countries in the Middle East. Under the terms of the agreement, SehaMed will leverage its network of distributors across the Gulf Cooperation Council to introduce ColoHealth.

Vizgen, Hamamatsu partner to streamline spatial biology workflows

August 2025—Vizgen and Hamamatsu Photonics have entered a strategic partnership that integrates Hamamatsu’s MoxiePlex multiplex immunofluorescence imaging system with Vizgen’s reagent and assay portfolio. The companies plan to combine their expertise through validated In­SituPlex panels, coupled with MoxiePlex, as an integrated multiplexed proteomic biomarker offering capable of multisite deployments for translational and clinical research applications.

IDT unveils infectious disease research solutions

August 2025—Integrated DNA Technologies has unveiled its PrimeTime influenza kit and PrimeTime research pathogen panels. The influenza kit is a qPCR solution designed to amplify common influenza strains and targets influenza A, influenza A (H5N1), influenza B, and RNase. It includes an internal control for sample quality assessment, a premixed primer and probe set, PrimeTime 4x Broad-Range Master Mix, and direct amplification enhancer.

MRC Holland assay for Peutz-Jeghers gains EU IVDR certification

August 2025—MRC Holland announced that its Salsa MLPA Probemix P101 STK11 assay for the detection of Peutz-Jeghers syndrome received the CE mark for in vitro diagnostic use under IVDR regulation EU 2017/746. The probe mix detects copy number variations in the STK11 gene and has been updated with two improved and two newly added denaturation control probes that facilitate the detection of denaturation issues with exceptional sensitivity, according to a company press statement.

SSI Diagnostica acquires Gulf Coast Scientific

August 2025—SSI Diagnostica Group is acquiring Gulf Coast Scientific (Oldsmar, Fla.), which specializes in the development of urea breath testing for Helicobacter pylori, to further strengthen its gastrointestinal disease testing portfolio. SSI Diagnostica, headquartered in Denmark, acquired CTK Biotech (Poway, Calif.) in 2020 and TechLab (Blacksburg, Va.) in 2022. Jointly the group will have a total revenue of approximately $125 million.

Waters acquires Halo Labs

August 2025—Waters Corp. announced it has acquired Halo Labs. Halo Labs’ Aura platform, which features a highly differentiated technology that performs full spectrum particle analysis, is complementary to the Waters light-scattering detection solutions from its Wyatt Technology portfolio. The subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T cells for cell therapy. By acquiring Halo Labs, Waters said it will be able to integrate the emerging technology into new and existing large molecule development and QA/QC.

Randox unveils Evidence RABTA

August 2025—Randox has launched the Evidence RABTA (random access biochip technology analyzer), capable of processing up to 60 samples per hour and delivering up to 2,640 test results per hour. The analyzer offers seamless random access capabilities, allows users to assign samples as priority, and uses single-use tips for aspiration and dispensing. The time to first result is 36 minutes, with up to 44 results per sample. Walkaway time is up to 2.5 hours.

CRCdx RAS mutation detection kit gets CMS coverage

August 2025—EntroGen announced that its CRCdx RAS mutation detection kit has received national coverage from the Centers for Medicare and Medicaid Services. CRCdx is an FDA-approved, real-time PCR-based companion diagnostic for use in identifying patients eligible for treatment with Vectibix (panitumumab), based on the absence of KRAS and NRAS mutations.

MARKETPLACE

TRENDING